Predictive Oncology Inc. (NASDAQ: POAI) Stands to Benefit from Explosive Growth of Precision Medicine
Precision medicine in oncology allows for clinicians to develop personalized cancer treatment plans using individual characteristics of each patient Doctors use insights drawn from laboratory-grown cancer cells, patients’ DNA to individualize cancer treatment Predictive Oncology has been forerunner in its field, both through Helomics division’s smart tumor profiling platform as well as TumorGenesis subsidiary, which creates the tools used in ovarian cancer research TumorGenesis has begun to commercialize intellectual property, having received first order for unique ovarian cancer cell culture media in June 2020 In the summer of 2018, 49-year-old Star Dolbier arrived at the University of Maryland Greenebaum Cancer…